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ABSTRACT 
Aim:  
Evaluate potential of newly-developed, biocompatible iron oxide magnetic nanoparticles 
(MNPs) conjugated with J591, an antibody to an extracellular epitope of prostate specific 
membrane antigen (PSMA), to enhance MRI of prostate cancer (PCa).  
Materials & Methods: 
Specific binding to PSMA by J591-MNP was investigated in vitro. MRI studies were performed 
on orthotopic tumor-bearing NOD.SCID mice 2h and 24hr after intravenous injection of J591-
MNPs, or non-targeting MNPs. 
Results and Conclusions: 
In vitro, MNPs did not affect PCa cell viability, and conjugation to J591 did not compromise 
antibody specificity and enhanced cellular iron uptake. In vivo, PSMA-targeting MNPs 
increased MR contrast of tumors, but not by non-targeting MNPs. This provides proof-of-
concept that PSMA-targeting MNPs have potential to enhance MR detection/localization of 
PCa., 
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INTRODUCTION 
Magnetic resonance imaging (MRI) is a useful imaging tool in prostate cancer (PCa) 
management. It provides excellent soft tissue contrast, multi-dimensional information, does 
not involve exposure to ionising radiation, and is non-invasive [1]. However, like other 
imaging modalities such as computed tomography (CT), transurethral ultrasound (TRUS) and 
nuclear imaging, MRI cannot adequately detect small tumors [2]. Improvements in tumor 
imaging technologies are urgently required for early detection of disease, staging, and/or real-
time assessment of response to therapy in PCa patients. Iron oxide magnetic nanoparticles 
(MNPs) have emerged as powerful contrast agents for MRI [3]. Their superparamagnetic 
properties make them effective at reducing transverse (spin-spin) T2-relaxation time, causing 
negative contrast in MR images [4, 5]. MNP-assisted MRI has the potential to improve the 
assessment of cell receptor expression on tumors, liver function (macrophage content and 
activity), inflammation, degenerative diseases, angiogenesis, perfusion and apoptosis [6]. 
Currently, certain iron oxide-based MNPs have been approved for use in clinical MRI, for 
instance ferumoxil (GastroMARK) enhance imaging of the bowel. In this study, we evaluate 
the potential ability of MNPs to enhance MRI of PCa. We conjugated MNPs to the prostate 
specific membrane antigen (PSMA)-targeting antibody, J591, via a 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[amino(polyethylene glycol) (PEG-DSPE) linkage, for delivery of the 
nanoparticle cargo to PCa cells. PSMA, a 750-amino acid, type 2 transmembrane glycoprotein 
with folate hydrolase or carboxy peptidase II activity [7], is an ideal molecular target for 
imaging for a number of reasons. While PSMA is expressed in normal prostate epithelial and 
benign hyperplastic cells, it exists as a truncated form (PSM’) through alternative splicing and 
is found in the cytosol, whereas a transmembane form is expressed at high levels in PCa [8]. 
The PSMA/PSM’ mRNA ratio is lowest in normal tissue and increases with increasing Gleason 
score [9]. PSMA expression is up-regulated in PCa, including lymph node and bone 
metastases, up-regulated in androgen deprivation conditions, and elevated in late stage 
  
castrate-resistant prostate cancer (CRPC) [10-12]. In addition, PSMA has a cytoplasmic 
domain that contains a novel and unique amino acid sequence of MXXXL that mediates its 
internalisation and endosomal recycling [13, 14], which can lead to high intracellular 
retention of PSMA-targeting biomaterials such as MNPs. J591 was selected as the PSMA-
targeting agent due to its well-established specificity. 177Lu-J591 was been previously shown 
to target all known sites of disease in all treated PCa subjects [15], and in another study, 
treatment with 111In-J591 and then 90Y-J591 revealed 89% of known bony metastases and 
69% of soft tissue lesions [16]. We provide proof-of-concept that J591-labeled MNPs can 
enhance MRI of orthotopic xenograft PCa in mice.  
 
MATERIALS & METHODS 
Preparation and characterisation of magnetic nanoparticles 
Monocrystalline iron oxide nanoparticles were synthesized using a  small modification of the 
solvent free one-pot procedure initially reported by Niederberger et al [17, 18]. Briefly, 
Fe(acac)3 powder (500 mg) was mixed with benzyl alcohol (10 mL) and sealed in a Teflon 
cup. The mixture was placed and tightly sealed in a steel container and transferred in a 
furnace at 175ºC for 48 h. A ligand exchange procedure with oleic acid was used to 
hydrophobise the synthesized nanoparticles.  The nanoparticle suspension in benzyl alcohol 
was centrifuged once and the pellet resuspended in chloroform (5 mL). Oleic acid was then 
directly added in excess (50uL) into the nanoparticle solution which was then immediately 
placed in a sonic bath for 60 min. The oleic acid capped nanoparticles were washed three 
times using high speed centrifugation to remove excess oleic acid. The oleic acid capped 
nanoparticles were used as solid templates for the formation of core-shell micellar hybrid 
structures. Typically, 1mL of a mixture of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[carboxyl (polyethylene glycol)] (DSPCE-PEG-COOH), 1,2-dimyristoyl-sn-glycero-3-
  
phosphoethanolamine-polyethylene glycol (DSPE-PEG) and L-alpha-phosphatidylcholine (PC) 
(20:50:30 %Weight 2mg/mL) in chloroform was prepared and mixed with the oleic acid 
capped nanoparticles (~10 umol Fe). To facilitate monitoring of cellular interactions, the 
lipophilic near-infrared (NIR) fluorescence probe 1,1'-dioctadecyl-3,3,3',3'-tetramethyl 
indotricarbocyanine Iodide (DIR) was added to the phospholipid mixture ( 0.5% Weight). The 
solvent was evaporated at 55°C and the samples were stored under nitrogen at -20 °C until 
used. The dry nanoparticle film was heated to 70 °C and rehydrated with 1mL H2O. Empty 
micelles were removed by a round of centrifugation at 14000 rpm and the pellet was 
resuspended in H2O. To enable conjugation with the J591 monoclonal antibodies, the terminal 
carboxyl groups of the DSPCE-PEG-COOH were activated using N-hydroxysuccinimide (NHS, 
50mM) and N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC, 100mM) 
for 10min. The nanoparticle suspensions were centrifuged and resuspended into 1 mL of PBS 
and quickly added to the antibody solution (75 ug antibody per 10 umol Fe). The mixture was 
left to react overnight after which the antibody conjugated nanoparticles were purified by 
centrifugation at 4 °C. Hydrodynamic diameters and polydispersity indexes were determined 
using a Zetasizer Nano ZS equipped with a 633 nm He-Ne laser (Malvern Instruments). 
Transmission electron microscopy (TEM) measurements were conducted using a Philips 
CM100 TEM. 
 
Cell lines 
The human prostate cancer cell lines LNCaP, PC3, DU145, 22RV1 (all sourced from American 
Type Culture Collection (ATCC), USA), BPH-1 (from Dr Simon Hayward, Vanderbilt University 
Medical Center, USA), LNCaP-C42B (abbreviated C42B) (from Dr Leland Chung, Cedars-Sinai 
Medical Center, USA) [19, 20], LNCaP-LN3 (from Dr Curtis Pettaway, MD Anderson Cancer 
Center, University of Texas, USA) and LNCaP-luc (generated in-house) were maintained in 
RPMI media containing 5% fetal bovine serum. LNCaP-luc cells were generated using the 
  
Viralpower Lentiviral gene expression system (Invitrogen, USA) according to the 
manufacturer’s instructions. Briefly, supernatant containing the lentivirus was mixed with 
polybrene (8 μg/ml) and used to infect LNCaP cells. After infection, positive transfectants 
were selected as a pool by treatment with blasticidine (8 μg/ml) for six days. RWPE-1 cells 
(ATCC) were grown in keratinocyte serum-free media (SFM) supplemented with recombinant 
human epidermal growth factor (5 ng/mL final concentration) and bovine pituitary extract 
(50 ng/mL). The J591 hybridoma (from Dr Neil Bander, Weill Medical Centre, Cornell 
University, USA) which produces the anti-PSMA antibody [21], was maintained in Hybridoma 
SFM. All media and supplements were sourced from Gibco, Life Technologies. All cell lines 
were incubated at 37°C in a humidified atmosphere of 5% C02/air. 
 
Purification of anti-PSMA antibody (J591) by affinity chromatography 
The hybridoma J591 was cultured as described until the media were exhausted, and the 
secreted antibody was harvested. The hydridoma culture supernatant was passed through a 
HiTrap Protein HP column (GE Healthcare, UK) according to the manufacturer’s instructions, 
on an AKTA FPLC system (GE Healthcare, UK). The bound IgG was eluted using 0.1 M glycine, 
pH 3, and the pH was immediately neutralized with 1 M Tris-base, pH 9.0. The eluates were 
dialysed against PBS and the purity of antibody preparations was determined by SDS-PAGE 
followed by Coomassie blue (Biorad, USA) staining. The concentration was determined by 
BCA protein assay (Pierce Biotechnology, USA). 
 
Flow cytometric detection of PSMA 
Cells were grown to 80% confluence in T75 flasks, washed twice in PBS then lifted using non-
enzymatic cell dissociation buffer (Sigma Aldrich, USA). Cells were then washed in PBS 
containing 5% FBS (FACSWASH) then resuspended at 106 cells/mL. 100 µL of cell suspension 
were incubated with affinity-purified J591 antibody on ice for 1 hour, and then washed thrice 
  
in FACSWASH. Cells were then incubated with a secondary AlexaFluor 488-labelled donkey 
anti-mouse IgG (H+L) antibody (Life Technologies, USA) for 30 mins on ice, before washing 
thrice in FACSWASH. Cells were then run on a FACS Canto (BD Bioscience, USA) and data 
analysed using Kaluza software (Beckman Coulter, USA).   
 
Cell toxicity assays 
The effect of MNPs on the viability of PCa cells was determined using Alamar blue reagent 
(Invitrogen, Life Technologies). Cells were seeded at 5,000 cells per well (100 µL volume) in a 
96-well plate, and cultured overnight in growth media. Various amounts of MNPs in 100 µL 
volume were added to the wells (see Figure 2 legend for amounts), and plates were returned 
to the incubator for 48 hours. 20 µL of Alamar blue reagent were added to all wells, which 
were then incubated at 37oC for 3-4 hours. 100 µL of supernatant were transferred to a black 
96 well plate, and fluorescence at 590nm was measured using a FLUOstar Omega plate reader 
(BMG Labtech, Germany).    
 
Prussian blue staining for uptake of MNPs 
For in vitro studies, cells grown on chamberslides or on cover slips were incubated for 2 hours 
at room temperature with MNP alone, MNPs conjugated to J591 (J591-MNP) or J591 alone. 
Cells were fixed in 2% paraformaldehyde, washed with PBS, and then stained for iron using 
the Accustain reagent (Sigma Aldrich, USA) according to the manufacturer’s instructions. 
Briefly, the cells were stained in Iron Staining solution for 10 minutes, rinsed in deionised 
water, and then counter-stained for 5 minutes in Pararosaniline solution for 5 minutes. The 
cells were rinsed in deionised water again, air-dried then mounted with a coverslip. For in 
vivo studies, all mice were euthanized immediately after MRI (approximately 24 hours post 
MNP injection), and the harvested tissues were fixed in 10% neutral buffered formalin for 48-
72 hours and then in 70% ethanol for a further 48 hours. The tissues were then processed on 
  
a Tissue-Tek VIP6 tissue processor, blocked in paraffin then sectioned at 5um thickness. The 
same Accustain protocol was used to perform iron staining of tissue sections.  
 
Fluorescence microscopy 
C42B cells grown on coverslips were incubated for 2 h at room temperature in the presence of 
MNPs alone, J591-MNP or J591 alone. Cells were washed, incubated with AlexaFluor-488 
donkey anti-mouse antibody (Life Technologies, USA) for 30 minutes at room temperature, 
washed PBS and then fixed in 2% paraformaldehyde. Cells were then washed once with PBS, 
and coverslips were mounted onto slides. Images were acquired on a Zeiss confocal 
microscope.  
 
Animal studies (orthotopic prostate xenograft model)  
All studies were in accordance with guidelines of the Animal Ethics Committees of Queensland 
University of Technology (QUT) and The University of Queensland (UQ), and Australian Code 
for the Care and Use of Animals for Scientific Purposes. LNCaP or bioluminescent LNCaP-luc 
cells were lifted from culture flasks with trypsin, washed twice with PBS and resuspended in 
PBS. Cell counts were performed with a haemocytometer and viability was assessed by trypan 
blue exclusion. For intraprostatic injections, hair was removed from the abdomen of mice 
using a hair clipper, and the mice were anaesthetised with ketamine (25mg/kg) and xylazine 
(5mg/kg) and received buprenorphine (0.1mg/kg) for analgesia. An incision at the midline of 
the abdomen of NOD/SCID mice was made through the skin, exposing the dorsal prostate. 
1x106 LNCaP-luc cells were injected into the dorsal prostate in 25 µl volume. The bladder was 
returned to the abdomen and the incision closed with sutures. Tumor development was 
monitored by bioluminescence imaging using an IVIS Spectrum (Xenogen, USA) weekly for a 
total of 4 weeks after tumor cell implantation. For bioluminescence imaging, mice were 
injected intraperitoneally with D-luciferin diluted in PBS (15 mg/mL stock) at 150 mg/kg. 
  
Mice were anaesthetised via isoflurane inhalationand imaged 8–12 minutes after injection 
with D-luciferin. Bioluminescence was analysed using Living Imagine software (Xenogen, 
USA).  
 
Magnetic resonance imaging (MRI) studies (Pilot studies) 
In experiments involving MRI on non-tumor bearing mice injected with MNPs directly into the 
prostate, mice were first anaesthetised with ketamine and xylazine. A small midline incision 
was made on the abdomen of NOD/SCID mice, exposing the dorsal prostate, and 12µg of 
MNPs in 20 µL volume were injected into it. MRI was performed 1h, 24h and 48 h thereafter. 
In experiments involving MRI on mice bearing orthotopic LNCaP or LNCaP-luc tumors, mice 
were injected with MNPs alone (n=2) or J591-MNP (n=3) intravenously via tail vein at 6 
mg/kg and MRI was performed 2 h and 24 h thereafter. This dosage was based on similar 
studies that also involved tail vein injection of MNPs to enhance MRI of other cancer types in 
rodents [22-24]. The well-being of all mice throughout the duration of the experiments, 
particularly after MNP administration, was closely monitored. We employed the animal 
welfare assessment methodology by  DB Morton [25]. All mice were euthanized by CO2 
asphyxiation immediately after their final MRI scan (24 h or 48 h, depending on experiment; 
see figure legends). Mice were imaged on a Bruker (Germany) AV700 MRI system consisting 
of a 16.4T vertical magnet interfaced to an AVANCE II spectrometer running Paravision 5 
using a 25 mm volume coil in a micro2.5 gradient set, under isofluorane anaesthesia. 
Recirculating water in the gradient set was maintained at 30°C. A series of fast low-resolution 
gradient echo (GE) images were acquired as localisers for placement of the following image 
sets. A series of axial GE images, centred on the prostate, were acquired with typical 
parameters as follows: TR = 252 ms, TE = 2.8 ms, pulse angle 30°, field-of-view = 30X30 mm, 
matrix = 320X320, slice thickness 0.8 mm, slice gap = 0 mm, number of slices = 19, numbers of 
averages = 12, acquisition time = 16 min.   
  
 RESULTS 
Characterisation of MNPs and J591 alone 
The magnetic nanoparticle preparation was developed based on the solvent-evaporation 
method initially reported for the preparation of quantum dots phospholipid micellar hybrids 
[26]. Highly monocrystalline magnetite nanoparticles were synthesized using the one-pot 
benzyl alcohol route described by Niederberger et al and further phase-transferred into 
chloroform using oleic acid as a capping agent. The oleic acid coated nanoparticles were then 
mixed with PEGylated phospholipids and the solvent evaporated. Rehydration of the dry film 
yielded the phospholipid coated magnetic nanoparticles which could be easily purified from 
empty micelles using centrifugation. Terminal carboxylic groups on the 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[carboxyl (polyethylene glycol)] were activated using 
EDC/NHS and further reacted with the J591 antibody to yield the immune-targeted MNPs. 
Characterization of the nanoparticles was carried on using transmission electron microscopy 
and dynamic light scattering measurements which showed that the sample consisted of small 
clusters of the magnetic nanoparticles (Figure 1A). The mean hydrodynamic diameter of the 
MNP clusters was 110 nm and the polydispersity index 0.127 as determined using dynamic 
light scattering (Figure 1B). Affinity-purified J591 antibody was shown to be specific for PSMA 
through binding only to known PSMA-positive cell lines (22RV1, LNCaP, and C42B cells) but 
not to those that are PSMA-negative (BPH-1, RWPE-1 and DU145 cells) as determined by flow 
cytometry (Figure 1C).    
 
MNPs are non-toxic to prostate cancer cells, 
To determine if MNPs has any toxic effects on cells, RWPE-1 cells (non-tumorigenic prostate 
cell line), LNCaP, C42B, PC3 and DU145 cells (tumorigenic cell lines) were incubated with 
various doses of MNPs alone for 48 hours. The viability of cells was not affected, as assessed 
by Alamar blue reagent (Figure 2).  
  
 
J591-MNP led to increased tumor uptake of iron, and binding of J591 to PSMA is not 
compromised when conjugated to MNPs  
To assess whether or not conjugation of MNPs with J591 facilitates iron uptake by tumors in 
vitro, C42B cells (PSMA-positive) were incubated with MNP alone or J591-MNP. Confocal 
microscopy shows minimal iron uptake in cells treated with MNPs alone, but significant 
uptake was seen with J591-MNP (Figure 3A). The J591 component of J591-MNP could also be 
visualised with the FITC-labelled anti-mouse secondary antibody. Similarly, Prussian blue 
staining showed greater iron uptake by LNCaP-LN3 cells (PSMA-positive) in vitro when 
incubated with J591-MNP than with MNP alone (Figure 3B top panel), confirming that 
conjugation of MNPs to J591 facilitated their uptake by the prostate cancer cells. The 
immunohistochemical staining intensity for PSMA by J591-MNP was similar to that of J591 
alone, indicating that conjugation of MNP did not compromise antibody binding to PSMA 
(Figure 3B bottom panel).  
 
Direct injection of MNPs into the prostate of mice induces negative contrast on MR images 
To provide proof-of-concept that the presence of MNPs within the prostate is detectable by 
MRI, non tumor-bearing mice were injected with MNPs alone directly into their normal 
prostate. MR images taken 1 hour after MNP injection showed significant darkening at that 
anatomical site. A similar degree of negative contrast was seen in the same mouse on MRI 
images taken 24 hours and 48 hours post-MNP injection (Figure 4). The darkening effect as a 
result of the MNP facilitated the visualisation and localisation of the prostate.  
 
Enhanced MRI of orthotopic xenograft LNCaP tumors by J591-MNP (Pilot study) 
To evaluate the potential of PSMA-targeting MNPs as an imaging agent for MRI of prostate 
cancer, MRI was performed on mice with pre-established orthotopic LNCaP-luc tumors and 
  
intravenously injected with either MNPs alone or J591-MNPs. MR images of tumors from mice 
that received the J591-MNP conjugates showed significant darkening at the prostate region, at 
the 2-hour and 24-hour post-injection timepoints (Figure 5). Negligible darkening effect was 
observed in mice that received intravenous MNPs alone (Figure 5). Prussian blue staining of 
resected tumors from J591-MNP mice showed significant accumulation of iron within the 
tumor. In contrast, little iron accumulation was seen in the tumors from the MNP alone group 
(Figure 6), suggesting improved tumor targeting by the conjugates. Iron uptake was strong in 
the spleens of all mice, independent of treatment group (Figure 6). A low level of iron uptake 
was seen in the liver of all mice, with no difference between the two groups.  
 
 
 
  
  
DISCUSSION       
 
PCa is currently imaged using MRI, TRUS and nuclear medicine [27]. However, these imaging 
techniques do not provide adequate detection for small tumor volumes or lymph node 
involvement [2]. The ability to accurately detect and locate small tumors is necessary for early 
detection of disease and for assessment of response to therapy in cancer patients. In recent 
years, the use of biomarker-targeted probes linked with nanoparticle-based contrast agents to 
enhance these imaging modalities has been a major area of research. In this study, we provide 
proof-of-concept that iron oxide MNPs conjugated with the PSMA-targeting antibody, J591, 
enhances MRI of prostate cancer in a preclinical model of orthotopic prostate cancer 
xenografts in mice.  
 
MRI is a highly desirable imaging technology because it is non-invasive, provides excellent 
soft tissue contrast, multidimensional morphological information, and does not involve 
exposure to ionising radiation [1]. MRI can be strongly enhanced through the employment of 
MNPs [1]. The presence of magnetic cores within the tissues decreases the relaxation times of 
the protons of surrounding water, causing a darkening effect at those sites in MR imaging. We 
showed that direct injection of MNPs into the prostate of mice (Figure 4) or intravenous 
injection of PSMA-targeting MNPs which homed to the orthotopic tumors (Figure 5), caused 
darkening at those anatomical locations in MR images. These observations have major clinical 
implications because tumor-targeting MNPs could potentially enable the early detection of 
tumors confined within the prostate by MRI. Although PSMA is expressed also on normal 
prostate cells, the level is significantly lower as compared to malignant cells. In addition, and 
very importantly, small metastases in lymph nodes and bone metastases may also be 
visualised using this technique. A key point is that lesions identified through our MNP-
  
assisted MRI approach are prostate-derived. Currently, MRI and CT use lymph node size to 
distinguish between those that are malignant or benign, an approach based on the premise 
that the enlargement of nodes is due to the accumulation of metastatic cells [28]. However, 
not all enlarged lymph nodes contain tumor cells, and normal-sized lymph nodes can also 
harbour metastases, hence false-positives and false-negatives remain as limitations. MNP-
enhanced MRI could potentially facilitate accurate nodal staging, independent of node size, an 
important prognostic factor [28]. Bone metastases are currently identified through 
radionuclide bone scans, and in the future this approach could be complemented with MNP-
enhanced MRI.  
 
An important consideration in the design of biomarker-targeting imaging probes is the 
biological characteristics of the biomarker itself. PSMA is an excellent prostate tumor 
biomarker to target for a number of reasons. Its expression is highly restricted to prostatic 
cells, although it has also been reported to be expressed on endothelial cells, and its level 
increases with higher cancer stages [29]. Unlike prostate specific antigen (PSA), the clinically 
used biomarker of prostate cancer, PSMA is still expressed on tumors from patients 
undergoing androgen deprivation therapy. But very importantly, the cytoplasmic domain of 
PSMA contains a novel motif of amino acid sequence MXXXL, that mediatesits internalisation 
and endosomal recycling via a clathrin-dependent mechanism [13, 14]. This leads to high 
intracellular uptake of ligands carrying nanoparticles such as MNPs or other compounds, an 
important quality that improves tumor imaging due to the retention of the contrast agent for 
longer duration. Indeed, we found that the MNP-mediated darkening effect on MR images 
lasted for at least 24 hours in live mice (Figure 5). The specificity of the targeting agent is also 
very important in the design of biomarker-targeting imaging probes. In this study, we used 
the J591 monoclonal antibody due to its well established specificity. 177Lu-J591 was been 
  
previously shown in a Phase II clinical trial to target all known sites of disease in all treated 
subjects [15]. In another study, treatment of patients with 111In-J591 and then with 90Y-J591 
revealed 89% of known bony metastases and 69% of soft tissue lesions [16]. The high 
specificity of J591 for PSMA was also confirmed by us using flow cytometric analysis of a 
panel of prostate cancer cell lines with known PSMA expression status (Figure 1B). When 
J591 was conjugated with our MNPs, the binding ability of the antibody to PSMA was not 
compromised (Figure 3), which collectively suggests that our imaging platform is stable, and 
shows promise for translation into the clinic. MNPs also have the potential to be easily 
adapted to other imaging technologies such as nuclear or optical modalities, to provide 
anatomical, functional and molecular information [3].  
 
Another major issue in the translation of nanotechnology into biomedical practice is the 
biocompatibility of the nanoparticles. MNPs have been demonstrated to be biocompatible and 
biodegradable [1]. It is suggested that following internalisation into cells, iron oxide cores 
degrade into iron ions which then incorporate into the haemoglobin pool [30]. In addition, 
coating of MNPs with biodegradable polymers such as dextran or PEG prevents 
agglomeration, which also improves biocompatibility [3]. In our own hands, MNPs did not 
affect the viability of a panel of prostate cell lines, including both benign and cancerous cell 
lines (Figure 2), and the well-being of mice 24-hours after MNP injection was not 
compromised (no changes to body weight, reflex, alertness, breathing rates, coating 
appearance, faecal texture etc… as compared to pre-injection; see Materials and Methods for 
details)”.. Currently, ferumoxil (GastroMARK), an iron oxide-based MNPs formulation, is 
approved for use in clinical MRI to enhance imaging of the bowel. However, there have been 
some reports of unwanted side-effects in MNP usage. Feridex, a formerly FDA-approved MNP 
agent administrated intravenously for imaging of the reticuloendothelial system that is based 
  
on the engulfment of MNPs by phagocytes, is known to cause back and groin pain, as well as 
inducing allergic reactions [31]. It is inevitable that intravenously injected MNPs, even those 
labelled with ligands to bind cell surface markers on cancer cells, will distribute to other body 
parts such as spleen and liver. From a clinical point of view, it is crucial to modify the MNPs 
(eg PEGylation) to limit their toxicity, and direct them to the anatomical site of interest via the 
attachment of a ligand to a cell surface tumor biomarker to improve imaging at that site. If 
efficient targeting is achieved, a lower overall dose could be used to create a good MRI signal, 
and therefore with lower potential side-effects.We found that when mice were injected with 
the targeted-MNPs, there was high iron uptake by the tumor, in contrast to those given non-
targeted MNPs, which had negligible uptake (Figure 6). This correlated with the enhanced 
imaging (negative contrast) of orthotopic tumors by J591-MNP (Figure 5). None of the tumors 
from either group were hemorrhagic, further confirming that the stronger signals seen in 
J591-MNP tumors were indeed due to greater MNP uptake from PSMA-targeting, and not from 
them being hemorrhagic (higher iron content). We also found that iron uptake was high in the 
spleens of mice, with no difference in the level between the two treatment groups (Figure 6). 
This finding is not surprising as only a small percentage of   PSMA-targeting MNPs is expected 
to accumulate within the tumor, with the remaining distributing through the whole body. 
There was also no difference in liver iron uptake between targeting and non-targeting MNPs 
groups (Figure 6), likely for the same reason. The level of uptake in the liver was lower than in 
the spleen, which is an intriguing finding since preferential liver uptake is usually observed 
for nanoparticles after intravenous administration. It might be related to the physicochemical 
properties of the phospholipid coated nanoparticles used in this study [32] and warrants 
further investigation.  
 
 
  
The use of nanoparticles as contrast agents for MRI of prostate cancer has been investigated 
by other groups as well. Abdolahi et al used a similar approach to us in that J591 was 
conjugated to MNPs, and showed that this complex enhanced MRI of LNCaP (PSMA-proficient) 
but not DU145 (PSMA-deficient) cells [33]. These results are consistent with ours, although 
their study was limited to in vitro work only. Tan et al. reported that conjugation of CLTI 
peptide, which is specific to fibrin-fibronectin complexes in stroma, provided MRI contrast 
enhancement of subcutaneous PC3 xenografts in mice [34]. While this approach did not target 
prostate cancer cells per se, it still effectively enhanced MR detection of these tumors with 
good contrast-to-noise ratio. Gao et al. designed a theranostics technology for prostate cancer, 
whereby MNPs conjugated with docetaxel and a single-chain antibody against prostate stem 
cell antigen [35]. When injected in mice bearing PC3M xenografts, the nanoparticles provided 
MRI negative contrast, as well as inhibited tumor growth and prolonged their survival. 
Together with the promising data presented here, this body of work confirm the relevance of 
immunotargeting-superparamagnetic nanoparticles towards improving MR imaging of 
prostate cancer.  
 
CONCLUSION 
We provide proof-of-concept that PSMA-targeted MNPs can effectively enhance MRI of 
prostate cancer in a preclinical model of the disease. Based on its biocompatibility, stability, 
together with its ability to enhance MRI, PSMA-targeting MNPs have promise to be translated 
into the clinic to improve the management of prostate cancer.  
 
FUTURE PERSPECTIVE 
  
MRI will continue to be a major imaging tool for prostate cancer over the next decade due to 
its many desirable features as discussed above. However, as there has been an explosion in 
interest in the application of nanotechnology to improve imaging methods in recent years, we 
anticipate that some of the exciting and innovative strategies currently in development will be 
translated into the clinic in the short to medium-term future, and indeed improve the 
management of cancer.  In particular, strategies involving the use of biomarker-targeted 
probes linked with nanoparticle-based contrast agents to enhance cancer imaging have great 
potential for diagnosis, staging (lymph node involvement) and for real-time imaging of 
treatment response.  
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Executive Summary 
Current status of prostate cancer imaging in the clinic 
 MRI is routinely used for imaging of prostate cancer (PCa); however, improvements 
in tumor specificity and sensitivity are required especially for small tumors.  
Development of a novel contrast agent to enhance MRI of PCa 
 PSMA is a cell surface membrane protein expressed highly on PCa but minimally on 
normal prostate tissue (ideal imaging target).  
 The superparamagnetic effect of iron oxide magnetic nanoparticles (MNPs) provides 
negative contrast in MRI. 
 In this study, we conjugated the PSMA-specific antibody, J591, to MNPs. The 
  
antibody delivers the MNP specifically to prostate cancer cells, while the MNP 
component provides negative contrast in MRI. 
Key findings of our nanoparticle-antibody system for MRI 
 MNPs did not affect the viability of prostate cancer cells per se, and were well 
tolerated by mice after injection. 
 Significantly greater tumor uptake of MNPs occurred when they were labelled with 
J591, both in vitro and in vivo, than non-targeted MNPs.  
 Importantly, J591-labelled MNPs localised to pre-established orthotopic tumors in 
mice, enhancing their detection by MR. High accumulation of iron was seen in these 
tumors; negligible accumulation for control group.    
The big picture 
 Our system has the potential to enhance PCa detection and localization in real-time, 
improving patient management. 
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FIGURES 
 
Figure 1. Characterisation of MNPs and J591 separately. A) TEM image of the MNPs as 
small aggregates. B) Hydrodynamic diameters of the iron oxide MNPs as synthesised (red 
line) and with the PEG-DSPE coating (blue line; abbreviated as MNPs). C) Flow cytometric 
analysis showed that the J591 antibody binds specifically to PSMA because positive staining 
was only detectable on PSMA-positive prostate cancer cells (22RV1, LNCaP and C42B) but not 
on PSMA-negative cells (BPH-1, RWPE-1, and DU145). 
 
  
  
 
Figure 2. MNPs are non-toxic to prostate cancer cells. Incubation of prostate cancer cell 
lines with various amounts of MNPs alone for 48 hours did not affect their viability, as 
assessed by Alamar blue viability assay. 
  
  
 
Figure 3. J591-MNP led to increased tumor uptake of iron, and binding of J591 to PSMA 
is not compromised when conjugated to MNPs. A) Confocal images of C42B cells after 
incubation with MNPs alone, J591-MNP or J591 alone, show that uptake of MNPs (DiR-
labelled; purple) is increased when conjugated to J591. The J591 component of J591-MNP 
could be visualised with the FITC-labelled secondary antibody. Images were acquired on a 
Zeiss confocal microscope. B) Prussian blue staining for iron (top panel; dark blue) showing 
  
greater iron uptake by LNCaP-LN3 cells with J591-MNP than MNP alone. 
Immunohistochemical staining for PSMA (bottom panel) shows that both J591-MNP, and J591 
alone, give the same level of staining on LNCaP-LN3 cells, indicating that conjugation of MNPs 
to J591 does not affect its binding and specificity for PSMA. Minimal staining was seen with 
MNP alone.  
   
  
  
 
Figure 4. Direct injection of MNPs into the prostate of non-tumor bearing mice causes 
darkening of MR images of the prostate. The prostate appears white/pale in MR images 
taken prior to MNP injection, but it appears black and granulated on MR images once MNP 
was injected (12ug of MNP in 20ul volume). This negative contrast effect was seen after 1-, 
24- and 48-hours post-MNP injection in the same live mouse. MR images of a representative 
mouse are shown.  
 
 
  
  
Figure 5: Enhancement of MRI with targeted MNP-J591 (pilot study).  Once the pre-
established LNCaP-luc tumors had reached the desired size (based on bioluminescence signal; 
inset), which occurred approximately 4-weeks post tumor cell injection, the mice were 
injected intravenously with MNPs alone (n=2) or J591-MNP (n=3). Administration of J591-
MNP conjugates resulted in significant darkening of MR images of the prostate region, at 2-
and 24-h post-injection. No darkening effect occurred in mice given MNPs alone. Red arrows: 
orthotopic LNCaP-luc tumors. MR images of representative mice from each group are shown. 
  
  
 
Figure 6: Targeting of orthotopic tumors is improved when J591 is conjugated to MNPs. 
Prussian blue staining showed significant iron uptake in resected LNCaP tumors from mice 
injected intravenously with J591-MNP (n=5), as compared to MNP alone (n=4). Similar high 
levels of iron uptake is observed in the spleens between J591-MNP and MNP alone mice. Low 
iron uptake was seen in liver from all mice. 
 
 
 
